593
Views
11
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis

, , , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 97-104 | Received 23 Jan 2017, Accepted 09 May 2017, Published online: 08 Jun 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Shin Yeu Ong, Colin Phipps, Chandramouli Nagarajan, Tiffany Tang, Soon Thye Lim, Yeow Tee Goh & Yuh Shan Lee. (2020) Cell-of-origin and bone marrow involvement increase specificity of defining patients with diffuse large B-cell lymphoma at high risk of CNS relapse: a study of 793 patients treated with chemoimmunotherapy in Asia. Leukemia & Lymphoma 61:1, pages 225-227.
Read now
Elisa Santambrogio, Maura Nicolosi, Francesco Vassallo, Alessia Castellino, Mattia Novo, Annalisa Chiappella & Umberto Vitolo. (2019) Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence. Expert Review of Hematology 12:9, pages 787-796.
Read now

Articles from other publishers (9)

Mingxiao Lang, Youqin Feng, Xiangrui Meng, Jing Zhao, Zheng Song, Zhengzi Qian, Lihua Qiu, Shiyong Zhou, Xianming Liu, Lanfang Li, Haiyan Yang, Yuqin Song, Wei Li & Huilai Zhang. (2021) Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis. Hematological Oncology 41:2, pages 239-247.
Crossref
Takafumi Shichijo, Hiro Tatetsu, Kisato Nosaka, Yusuke Higuchi, Yoshitaka Kikukawa, Yoshitaka Inoue, Kosuke Toyoda, Jun‐ichirou Yasunaga & Masao Matsuoka. (2022) Predictive impact of soluble interleukin‐2 receptor and number of extranodal sites for identification of patients at very high risk of CNS relapse in diffuse large B‐cell lymphoma. eJHaem 3:2, pages 385-393.
Crossref
Yangyang Wang, Jiyu Wang, Fengfeng Zhu, Huiping Wang, Liuying Yi, Keke Huang & Zhimin Zhai. (2022) Elevated circulating myeloid‐derived suppressor cells associated with poor prognosis in B‐cell non‐Hodgkin's lymphoma patients. Immunity, Inflammation and Disease 10:5.
Crossref
Zhitao Wang, Rui Jiang, Qian Li, Huiping Wang, Qianshan Tao & Zhimin Zhai. (2021) Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients. Journal of Clinical Medicine 10:8, pages 1768.
Crossref
Pamela McKay, Matthew R. Wilson, Sridhar Chaganti, Jeffery Smith, Christopher P. Fox & Kate Cwynarski. (2020) The prevention of central nervous system relapse in diffuse large B‐cell lymphoma: a British Society for Haematology good practice paper. British Journal of Haematology 190:5, pages 708-714.
Crossref
Teresa Calimeri & Andrés J.M. Ferreri. (2020) Prevention of CNS relapse in diffuse large B‐cell lymphoma: common sense prevails where science fails. British Journal of Haematology 190:5, pages 645-647.
Crossref
Tracy O'Connor, Xiaolan Zhou, Jan Kosla, Arlind Adili, Maria Garcia Beccaria, Elena Kotsiliti, Dominik Pfister, Anna-Lena Johlke, Ankit Sinha, Roman Sankowski, Markus Schick, Richard Lewis, Nikolaos Dokalis, Bastian Seubert, Bastian Höchst, Donato Inverso, Danijela Heide, Wenlong Zhang, Petra Weihrich, Katrin Manske, Dirk Wohlleber, Martina Anton, Alexander Hoellein, Gitta Seleznik, Juliane Bremer, Sabine Bleul, Hellmut G. Augustin, Florian Scherer, Uwe Koedel, Achim Weber, Ulrike Protzer, Reinhold Förster, Thomas Wirth, Adriano Aguzzi, Felix Meissner, Marco Prinz, Bernd Baumann, Uta E. Höpken, Percy A. Knolle, Louisa von Baumgarten, Ulrich Keller & Mathias Heikenwalder. (2019) Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. Cancer Cell 36:3, pages 250-267.e9.
Crossref
Roopesh Kansara. (2018) Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma. Current Treatment Options in Oncology 19:11.
Crossref
Joel C. Wight, Geoffrey Chong, Andrew P. Grigg & Eliza A. Hawkes. (2018) Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Reviews 32:5, pages 400-415.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.